Core Insights - Aishalon officially listed on the Beijing Stock Exchange on January 21, marking a new chapter in its capital market journey [1] - The company, established in 2015, focuses on the research, production, and sales of disposable medical consumables in rehabilitation care and medical protection [1] Group 1: Business Model and Partnerships - Aishalon specializes in disposable medical consumables such as medical nursing pads and surgical drapes, primarily through ODM/OEM models for international medical device brands [2] - The company has established long-term strategic partnerships with notable brands including Medline Group (USA), Zarys Group (Poland), and Sejong Healthcare (South Korea) [2] - The chairman highlighted that the company has maintained relationships with core clients for over ten years, contributing to stable performance despite high customer concentration [2] Group 2: Innovation and R&D - As of the signing date of the prospectus, Aishalon holds 77 patents, including 21 invention patents, with a continuous increase in R&D investment focused on product performance upgrades and new product development [3] - The company plans to gradually develop its own brand while maintaining its ODM/OEM foundation, aiming for higher market value [3] Group 3: Future Growth and Strategy - The successful issuance and subsequent fundraising will allow Aishalon to expand existing production capacity and increase R&D investment in new medical consumables [4] - The company aims to transition from a single dressing manufacturer to a broader medical consumables manufacturing and service platform, reducing dependency on single products and clients [4] - Aishalon is establishing a global production footprint with a core domestic base and new facilities in Thailand and Morocco, demonstrating strategic vision to adapt to international trade changes and cost pressures [4]

Core Insights - Aishalon Medical Technology Group Co., Ltd. officially listed on the Beijing Stock Exchange on January 21, 2026, becoming the first A-share listed company in Jiangsu Province this year and the first in Suzhou's Xiangcheng District [2] - The company's stock opened with a significant increase of 224.78%, reaching a total market capitalization of 3.49 billion yuan [2] Company Overview - Aishalon Medical focuses on the research, production, and sales of disposable medical consumables in the fields of rehabilitation care and surgical infection control [3] - The company has established long-term strategic partnerships with several international medical device brands, including Medline Group from the U.S., Zarys Group from Poland, and Sejong Healthcare from South Korea [3] - Aishalon is recognized as the largest manufacturer of medical care pads in China, with annual output value exceeding 500 million yuan from 2022 to 2024, positioning itself among the top players in the domestic medical dressing industry [3] Financial Performance - From 2022 to 2024, Aishalon's operating revenue grew from 574 million yuan to 692 million yuan, while net profit increased from 63 million yuan to 81 million yuan, demonstrating a steady compound annual growth rate [4] - For the first nine months of 2025, the company achieved an operating revenue of 689 million yuan, a year-on-year increase of 42.84%, and a net profit of 73 million yuan, up 27.50% from the previous year [4] - The company has maintained a high proportion of overseas sales revenue, which reached 96.54% in the first half of 2025, indicating its strong role in the global supply chain [4] Industry Context - The medical dressing industry is characterized by rigid demand, driven by global aging populations, increasing surgical volumes, and heightened infection control awareness [5] - The market for medical dressings is expected to continue growing steadily, with a trend towards high-quality, multifunctional, and disposable products [5] Growth Strategy - Aishalon plans to use the funds raised from its IPO to invest in the "Kaipule Public Health Medical Supplies Industrial Park" project, aimed at expanding production capacity and developing new product lines [6] - The company is transitioning from a single dressing production focus to a broader medical consumables manufacturing and service platform, which is expected to reduce dependency on single products and clients [6] - Aishalon is also expanding its global production footprint, with existing bases in Thailand and plans for new facilities in Morocco, showcasing its strategic vision to adapt to international trade dynamics and cost pressures [6]